AUTHOR=Hou Xiaofeng , Chen Chao , Lan Xiabin , He Xiaodong 

TITLE=Unveiling the molecular features, relevant immune and clinical characteristics of SIGLEC15 in thyroid cancer

JOURNAL=Frontiers in Immunology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.975787

DOI=10.3389/fimmu.2022.975787

ISSN=1664-3224

ABSTRACT=<p>The groundbreaking research work about <italic>SIGLEC15</italic> has raised it as a potential promising target in cancer immunotherapy. Unfortunately, the role of <italic>SIGLEC15</italic> in thyroid carcinoma (THCA) remains obscure. Public and home multi-omics data were collected to investigate the role of <italic>SIGLEC15</italic> in THCA in our study. <italic>SIGLEC15</italic> was upregulated in THCA tumor tissue compared to nontumor tissue in both mRNA and protein levels; gene set enrichment analysis (GSEA) results showed that high <italic>SIGLEC15</italic> mRNA expression was positively correlated to many immune pathways. Results of the examination of immunological landscape characteristics displayed high <italic>SIGLEC15</italic> mRNA expression that mainly positively correlated with a large number of cancer immunity immunomodulators and pathways. In addition, upregulation of <italic>SIGLEC15</italic> was positively correlated with an enhanced immune score, stromal score, and estimate score. However, higher <italic>SIGLEC15</italic> mRNA also met high immune exhausted status. The majority of CpG methylation sites negatively correlated with <italic>SIGLEC15</italic> mRNA expression. Analysis of clinical characteristics supported increased <italic>SIGLEC15</italic> expression that was positively correlated with more extrathyroid extension and lymph node metastasis. We observed different single nucleotide variant (SNV) and copy number variation (CNV) patterns in high and low <italic>SIGLEC15</italic> mRNA expression subgroups; some vital DNA damage repair deficiency scores addressed a negative correlation with <italic>SIGLEC15</italic> mRNA expression. We also found that some commonly used chemotherapy drugs might be suitable for different <italic>SIGLEC15</italic> mRNA expression subgroups. This study highlighted the vital role of <italic>SIGLEC15</italic> in THCA. Targeting <italic>SIGLEC15</italic> may offer a potential novel therapeutic opportunity for THCA patients. However, the detailed exact cellular mechanisms of <italic>SIGLEC15</italic> in THCA still needed to be elucidated by further studies.</p>